Navamedic ASA (Norway) Management Evaluation
| NAVA Stock | NOK 21.80 0.70 3.32% |
Navamedic ASA employs about 28 people. The company is managed by 13 executives with a total tenure of roughly 63 years, averaging almost 4.0 years of service per executive, having 2.15 employees per reported executive. Inspection of Navamedic ASA's management performance can provide insight into the company performance.
| Kathrine Andreassen CEO Chief Executive Officer |
| Magnus Emmoth CEO Chief Executive Officer of Navamedic Medtech AB |
Navamedic |
Navamedic ASA Management Team Effectiveness
The company has return on total asset (ROA) of 0.0633 % which means that it generated a profit of $0.0633 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.073 %, meaning that it generated $0.073 on every $100 dollars invested by stockholders. Navamedic ASA's management efficiency ratios could be used to measure how well Navamedic ASA manages its routine affairs as well as how well it operates its assets and liabilities.Navamedic ASA Workforce Comparison
Navamedic ASA is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,357. Navamedic ASA maintains roughly 28.0 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.03 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.1 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.1. Navamedic ASA Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Navamedic ASA Price Series Summation is a cross summation of Navamedic ASA price series and its benchmark/peer.
Navamedic ASA Notable Stakeholders
A Navamedic ASA stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Navamedic ASA often face trade-offs trying to please all of them. Navamedic ASA's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Navamedic ASA's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kathrine Andreassen | Chief Executive Officer | Profile | |
| Magnus Emmoth | Chief Executive Officer of Navamedic Medtech AB | Profile | |
| Terje Bakken | Chairman of the Board | Profile | |
| Lars Hjarrand | Chief Financial Officer | Profile | |
| Jostein Davidsen | Director | Profile | |
| Narve Reiten | Director | Profile | |
| Inger Solberg | Director | Profile | |
| Mattias Haartman | Marketing & Sales Director | Profile | |
| Cheng Lu | Director | Profile | |
| PerAnders Elvertro | Chief Commercial Officer, Head of Regulatory Affairs and Drug Safety | Profile | |
| Astrid Bratvedt | Chief Officer | Profile | |
| Mattias Hartmann | Marketing Director | Profile | |
| Ole Eriksen | Chief Officer | Profile |
About Navamedic ASA Management Performance
The success or failure of an entity such as Navamedic ASA often depends on how effective the management is. Navamedic ASA management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Navamedic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Navamedic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway. NAVAMEDIC ASA operates under Healthcare Products classification in Norway and is traded on Oslo Stock Exchange. It employs 26 people.
Navamedic ASA Workforce Analysis
Traditionally, organizations such as Navamedic ASA use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Navamedic ASA within its industry.Navamedic ASA Manpower Efficiency
Return on Navamedic ASA Manpower
| Revenue Per Employee | 9.9M | |
| Revenue Per Executive | 21.4M | |
| Net Income Per Employee | 84.2K | |
| Net Income Per Executive | 181.4K | |
| Working Capital Per Employee | 535.7K | |
| Working Capital Per Executive | 1.2M |
Other Information on Investing in Navamedic Stock
Navamedic ASA financial ratios help investors to determine whether Navamedic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Navamedic with respect to the benefits of owning Navamedic ASA security.